PD

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

Retrieved on: 
måndag, juni 3, 2024
Șaeș, ASCO, RECIST, Lung, CDK2, Vomiting, Fatigue, Endometrial cancer, Patient, Diarrhea, Annual general meeting, NSCLC, Safety, Society, Pharmacokinetics, Pancreatic cancer, Cyclacel, CDKN2B, PD, CDK9, T-cell lymphoma, CDKN2A, Lymphoma, CYCC, Poster, Hyperglycemia, Nausea, Pharmaceutical industry

BERKELEY HEIGHTS, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data from the CYC065-101 study of fadraciclib as oral monotherapy was presented at a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago, IL. See link to poster here.

Key Points: 
  • “We are excited to report data with fadraciclib monotherapy from the entire Phase 1 population at ASCO.
  • Clinical benefit was observed in heavily pretreated patients with several tumor types, including endometrial, lung, ovarian, pancreatic cancer, and T-cell lymphoma,” said Spiro Rombotis, President and Chief Executive officer.
  • In addition, clinical benefit was reported in two patients with endometrial cancer, and one each with ovarian and pancreatic cancers.
  • The proof of concept part of the study is now enrolling patients with CDKN2A/B loss or T-cell lymphoma.

Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024

Retrieved on: 
måndag, juni 3, 2024
ENDO, Therapy, QID, Entera, Injection, Patient, Annual general meeting, Serum, Trial of the century, Safety, Ish-Shalom, Teriparatide, Hypoparathyroidism, Life, Hypercalcaemia, Blood, PD, PTH, Calcium, Vital signs, BID, Endocrine Society, Tablet

Entera’s EB612 program aims to provide the first oral PTH daily tablet hormone replacement therapy for patients suffering from hypoparathyroidism.

Key Points: 
  • Entera’s EB612 program aims to provide the first oral PTH daily tablet hormone replacement therapy for patients suffering from hypoparathyroidism.
  • Late stage investigational PTH replacement treatments include TransCon PTH (palopegteriparatide) by Ascendis Pharma A/S and eneboparatide (AZP-3601) by Amolyt Pharma.
  • Entera previously published positive Phase 2a study results in hypoparathyroid patients with four times a day (QID) regimen (Ish-Shalom, JBMR 2021) of EB612.
  • “The encouraging findings from this Phase 1 study reaffirm the ability of our N-Tab™ platform to develop simple oral tablet treatments of important peptide therapeutics.

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Retrieved on: 
lördag, juni 1, 2024
MD, Aes, Șaeș, Biomarker, ASCO, Uveal melanoma, Fatigue, Toxicity, Carcinoma, Melanoma, Plasma, Patient, Diarrhea, Annual general meeting, ACC, Neutropenia, Acute leukemia, Safety, MD Anderson Cancer Center, Resource, Society, DL2, Therapy, ALL, Appetite, AML, Arm, Thrombocytopenia, MDM2, DL, Arthralgia, Messenger, Adenoid cystic carcinoma, Lymphoma, Blood, Acute myeloid leukemia, CDKN1A, PD, TPD, MPN, Grade 3, Merkel-cell carcinoma, MCC, University, Poster, Therapeutic index, Nausea, Pharmaceutical industry

WATERTOWN, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared new clinical data from its ongoing KT-253 Phase 1 trial. KT-253, a potent, selective heterobifunctional small molecule degrader of MDM2, demonstrated preliminary signs of efficacy across tumor types at doses that were generally well-tolerated. The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 – June 4, 2024. Results released in an ASCO poster today include a data cut-off of April 9, 2024.

Key Points: 
  • The data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31 – June 4, 2024.
  • Results released in an ASCO poster today include a data cut-off of April 9, 2024.
  • “We’re encouraged by the data emerging from the KT-253 Phase 1 dose escalation trial, showcasing the potential of TPD to address this clinically proven but inadequately drugged cancer mechanism.
  • Kymera is also developing a biomarker-based patient selection strategy for subsequent development beyond Phase 1a and is expected to present data at a medical meeting this year.

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
lördag, juni 1, 2024
Diamond, GBM, ASCO, Temozolomide, IC50, Patient, Fatigue, AACR, HGG, Diarrhea, Annual general meeting, Cancer, Safety, Glioblastoma, Stomatitis, Society, Pharmacokinetics, Dana–Farber Cancer Institute, Paronychia, EGFR, Diagnosis, PD, Lung cancer, Rash, Brain, TKI, Recurrence, Nausea, Conference, Medical imaging

CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today presented additional data from the Phase 1 dose escalation trial of BDTX-1535 in patients with recurrent glioblastoma (GBM), and initial data from a phase 0/1 “trigger” (“window of opportunity”) investigator-sponsored trial at the American Society of Clinical Oncology (ASCO) Annual Meeting. Clinical data from these trials in patients with recurrent GBM demonstrated brain penetrance of BDTX-1535, as well as safety and tolerability data similar to what has been previously described for patients with non-small cell lung cancer (NSCLC). In addition, the Phase 1 trial demonstrated encouraging anti-tumor activity and duration of treatment for patients with previously treated GBM.

Key Points: 
  • In addition, the Phase 1 trial demonstrated encouraging anti-tumor activity and duration of treatment for patients with previously treated GBM.
  • Patients received increasing doses of BDTX-1535 in 21-day cycles to assess safety/tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity.
  • Five patients remained on BDTX-1535 treatment for ≥4 months, 1 patient for ≥6 months, and 3 patients for ≥10 months.
  • Patients achieving the PK threshold were enrolled in the post-resection component of the study with an update expected in the fourth quarter of 2024.

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

Retrieved on: 
torsdag, maj 30, 2024
PD, Translational medicine, Atopic dermatitis, Therapy, Trial of the century, Skin, Asthma, Senior, Congress, Pathology, CSU, Patient, Cell, EAACI, Research, CD117, B cell, Antibody, Pharmaceutical industry

The two preclinical studies being presented at EAACI showed the potential of briquilimab in asthma and atopic dermatitis (AD), respectively.

Key Points: 
  • The two preclinical studies being presented at EAACI showed the potential of briquilimab in asthma and atopic dermatitis (AD), respectively.
  • The asthma study demonstrated that a single dose of briquilimab can deplete mast cells in both inflamed and non-inflamed tissue as well as improve lung function in an allergen-induced asthma model.
  • In the AD study, treatment with briquilimab led to a reduction of dermal mast cells and inflammatory leukocytes, indicating that mast cells play a critical role in the pathogenesis of AD and that briquilimab has the potential to reverse AD pathology by depleting those cells.
  • Both preclinical studies utilized Jasper’s proprietary c-Kit Mouse™, which overcomes the limitations of standard models that do not bind antibodies directed at the human c-Kit receptor.

PagerDuty to Present at Upcoming Conferences

Retrieved on: 
fredag, maj 31, 2024
Software, Technology, Artificial Intelligence, Data Management, Conference, Bank, PD

PagerDuty, Inc. (NYSE:PD), a global leader in digital operations management, today announced that members of its management team will present at the Bank of America Global Technology Conference 2024 on Tuesday, June 4th at 2:20 pm ET and the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th, at 5:40 pm ET.

Key Points: 
  • PagerDuty, Inc. (NYSE:PD), a global leader in digital operations management, today announced that members of its management team will present at the Bank of America Global Technology Conference 2024 on Tuesday, June 4th at 2:20 pm ET and the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th, at 5:40 pm ET.

PagerDuty Announces First Quarter Fiscal 2025 Financial Results

Retrieved on: 
torsdag, maj 30, 2024
Data Management, Technology, Software, Networks, Artificial Intelligence, Internet, Operate, PMO, Share repurchase, FedRAMP, Judgement, PD, Debt-to-GDP ratio, Average cost, Tax, News, Net, Investment, Exercise, Regulation Fair Disclosure, Bank statement, Marketing, Convertible, Regulation, Growth, Employee stock ownership, Social media, Note, PagerDuty, Acquisition, GAAP, Loss, Table, Veteran, Public expenditure, Disclosure, Bank

PagerDuty, Inc. (NYSE:PD), a leader in digital operations management, today announced financial results for the first quarter of fiscal 2025, ended April 30, 2024.

Key Points: 
  • PagerDuty, Inc. (NYSE:PD), a leader in digital operations management, today announced financial results for the first quarter of fiscal 2025, ended April 30, 2024.
  • “PagerDuty delivered a solid first quarter with annual recurring revenue growth stabilizing at 10% for the second consecutive quarter, and non-GAAP operating margin four percentage points above the range,” said Jennifer Tejada, Chairperson and CEO, PagerDuty.
  • The section titled “Non-GAAP Financial Measures” below contains a description of the non-GAAP financial measures and reconciliations between historical GAAP and non-GAAP information.
  • PagerDuty encourages investors to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate PagerDuty’s business.

Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors

Retrieved on: 
torsdag, maj 30, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Pharmacokinetics, Pembrolizumab, PD, NK, Messenger, Tumor microenvironment, Therapy, Neoplasm, Safety, Cancer, ASCO, Society, Immunotherapy, Entrepreneurship, Annual general meeting

Strand Therapeutics , the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient has been dosed in their Phase 1, first-in-human trial of STX-001, an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.

Key Points: 
  • Strand Therapeutics , the world’s first programmable mRNA company developing curative therapies for cancer, autoimmune diseases, and beyond, today announced the first patient has been dosed in their Phase 1, first-in-human trial of STX-001, an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.
  • “STX-001 represents the first programmable mRNA therapy in oncology to enter the clinic for the treatment of solid tumors,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics.
  • Strand will present a poster on the Phase 1 trial design.
  • The Phase 1 trial is an open-label, multi-center first-in-human dose-escalation trial, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of STX-001 alone, or in combination with pembrolizumab in patients with treatment refractory advanced solid tumors.

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history

Retrieved on: 
onsdag, maj 29, 2024
Patient, DNA, PD, Sleep, African, Risk, Tremor, Anosmia, Disease, Health, Parkinson's disease, PIP, Database, Dream, Research, REM, Movement, Hyposmia, Smell, Mediterranean Basin, Ashkenazi Jews, History, PRS, RBD, Pharmaceutical industry

Fox Foundation for Parkinson’s Research, conducted the world’s largest study on LRRK2 G2019S and uncovered new insights into the variant.

Key Points: 
  • Fox Foundation for Parkinson’s Research, conducted the world’s largest study on LRRK2 G2019S and uncovered new insights into the variant.
  • Yet, the LRRK2 G2019S variant is the most common pathogenic variant linked to Parkinson’s disease.
  • 23andMe’s study showed that people with the G2019S variant are seven times more likely to develop Parkinson’s than people without the variant.
  • People who develop Parkinson’s disease who have the LRRK2 G2019S variant have milder symptoms than those with Parkinson's who do not have the LRRK2 variant.

First European Surgeries Completed Using Stryker’s Gamma4 Hip Fracture Nailing System

Retrieved on: 
onsdag, maj 29, 2024
General Health, Surgery, Medical Devices, Health, Health Technology, CE, Faculty, PD, LES, Hospital de Sant Pau, University Hospital Heidelberg, Surgeon, Engineering, Philosophy, Certification, Anatomy, Professor, Hospital, SYK, Multimedia, Hip, Dentistry

View the full release here: https://www.businesswire.com/news/home/20240528327447/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240528327447/en/
    Stryker's Gamma4 Hip Fracture Nailing System is designed to treat hip and femur fractures.
  • (Photo: Business Wire)
    The Gamma4 Hip Fracture Nailing System is designed to treat hip and femur fractures.
  • “This moment marks a significant milestone, as the Gamma4 Hip Fracture Nailing System enters the European market, following the successful launch in the United States,” said Markus Ochs, vice president and general manager of Stryker’s European Trauma & Extremities business.
  • To discover more about the Gamma4 Hip Fracture Nailing System, visit stryker.com .